Supplementary Figure 6 from Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors
Francesco Facchinetti, Antoine Hollebecque, Rémy Barbé, Dong Man Jang et autres
0 citations
Héloïse Bourien
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
56Publications signalées
623Citations signalées
3Affiliations récentes
Institutions déclarées
Domaines associés
Hepatocellular Carcinoma Treatment and PrognosisCholangiocarcinoma and Gallbladder Cancer StudiesFibroblast Growth Factor ResearchCancer Genomics and DiagnosticsEosinophilic Disorders and Syndromes
Publications récentes
Supplementary Figure S1 from Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors
Francesco Facchinetti, Antoine Hollebecque, Rémy Barbé, Dong Man Jang et autres
0 citations
Supplementary Figure S2 from Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors
Francesco Facchinetti, Antoine Hollebecque, Rémy Barbé, Dong Man Jang et autres
0 citations
Supplementary Figure S5 from Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors
Francesco Facchinetti, Antoine Hollebecque, Rémy Barbé, Dong Man Jang et autres
0 citations
Supplementary Figure S4 from Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors
Francesco Facchinetti, Antoine Hollebecque, Rémy Barbé, Dong Man Jang et autres
0 citations
Supplementary Table S1 from Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors
Francesco Facchinetti, Antoine Hollebecque, Rémy Barbé, Dong Man Jang et autres
0 citations
Supplementary Figure S3 from Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors
Francesco Facchinetti, Antoine Hollebecque, Rémy Barbé, Dong Man Jang et autres
0 citations
Supplementary Table S3 from Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors
Francesco Facchinetti, Antoine Hollebecque, Rémy Barbé, Dong Man Jang et autres
0 citations
Supplementary Table S2 from Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors
Francesco Facchinetti, Antoine Hollebecque, Rémy Barbé, Dong Man Jang et autres
0 citations
Data from Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors
Francesco Facchinetti, Antoine Hollebecque, Rémy Barbé, Dong Man Jang et autres
0 citations
Second-line practices in the era of immunotherapy in HCC: The CHIEF cohort
Marie Decraecker, Héloïse Bourien, E.M. Thiam, Julien Edeline et autres
0 citationsJHEP Reports
18 F-FDG and 18 F-Fluorocholine PET as Prognostic Biomarkers in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Prospective Multicenter Study
Alexandre Cochet, Victor Besson, Aurélie Bertaut, A. Fouquier et autres
0 citationsJournal of Nuclear Medicine
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.